This week, I have an announcement to make.

Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyout

A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals

More CRISPR data, oncology wins, and a new player in ophthalmology

Billion-dollar acquisitions, troubled waters for some biotech’s, and a prosperous outlook for others

Some statistically significant guidance, seed to acquisition, some biobucks, and the CART of the future

One biotech is on a roll, another is moving quickly, Amazon money for cancer, and some clinical development news

Biotech’s with a series A, a series C, some debt financing, and there is even a Biopharma heading for a SPAC

Major Alzheimer’s news, an ALS approval, and expanded therapies for skin conditions

A $900 raise, gene therapy news, a quick IPO, and merge three for $100M

A critical aesthetics approval, site network buy-up, a very normal oncology biotech, and a busy week for one company.

A $1.1B acquisition, two FDA approvals, and grants for mRNA vaccines.

Ophthalmology acquisitions, following the pharma trends, and a move in healthcare that is not technology related.

Gene therapy approval, opioid costs continue, a $650M deal, and a $3.5B RNA partnership.

Spending that COVID money, brain money, Irish money, and another oncology approval

We take a break from stories of raising capital, mergers, and FDA approvals to look at the dark side of our industry. What happens when companies fail, people lie, and good drugs make bad lives?

There’s a SPAC, expanded FDA approval, more of the common, and two Bs, two As

Cell therapy acquisition, royalties sold, biobucks-like deal, successful raise, and Chinese Venture Capital

Feed Drop - Interview with Private Equity leader Dan Agroskin from Clinical Research Evolved Podcast

Double acquisition, private money, cheap deals, and a surprising $70M launch